APA (7th ed.) Citation

M, T., H, M., T, T., K, T., K, I., M, I., . . . H, I. (2026). Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis. Cancer science, 117(4), 1106. https://doi.org/10.1111/cas.70307

Chicago Style (17th ed.) Citation

M, Takahashi, et al. "Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis." Cancer Science 117, no. 4 (2026): 1106. https://doi.org/10.1111/cas.70307.

MLA (9th ed.) Citation

M, Takahashi, et al. "Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis." Cancer Science, vol. 117, no. 4, 2026, p. 1106, https://doi.org/10.1111/cas.70307.